Xiangzhen Liu

No ORCID on file · 1 paper in corpus
observational 2021
BMC cancer ·doi:10.1186/s12885-021-07869-7

BACKGROUND: The aim of this study was to assess the survival outcomes of cisplatin-paclitaxel chemotherapy plus bevacizumab (CPB) versus cisplatin-paclitaxel chemotherapy alone (CPA) in postmenopausal women with previously untreated advance…